3D Ex Vivo PDX Cell Model Screening to Better Predict In Vivo Outcome
Xiaoxi Xu, Chunlan Dong, Songling Zhang, Yan Liu, Fanxiu Meng, Yu Lu, Frank Xing, and Qian Shi
Patient-derived xenograft (PDX) models are in high demand in preclinical drug development due to their advantages over conventional 2D culture systems. These include a close molecular, histopathological, and heterogeneic reflection of the original tumor (more highly conserved than cell lines/GEMM) and the correlation between PDX and clinical drug response profiles.
Using PDX models does bring some limitations e.g. low throughput in candidate drug screening, time consuming studies, and progressive loss of human-derived stromal elements over passages.
To overcome these disadvantages, CrownBio has developed a robust and reproducible ex vivo 3D assay platform using cells isolated from early passage PDX models across lung, liver, gastric, colorectal and pancreatic tumors. This platform facilitates compound testing and screening, and provides bioinformatics information for data interpretation.
Read this Poster to Discover:
- That consistent results are demonstrated between different passages of the same PDX model
- That over 70% correlation is shown in a retrospective analysis of in vivo data with our ex vivo results, via a Pearson model
- How these panels can be used for standard of care drug screening, with varying efficacy observed for SoC agents tested across the colorectal PDX cell model panel